恒瑞医药
(600276)
| 流通市值：3368.75亿 | | | 总市值：3368.75亿 |
| 流通股本：63.79亿 | | | 总股本：63.79亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 7,205,611,122.72 | 27,984,605,342.06 | 20,189,303,845.1 | 13,600,734,114.77 |
| 营业收入 | 7,205,611,122.72 | 27,984,605,342.06 | 20,189,303,845.1 | 13,600,734,114.77 |
| 二、营业总成本 | 5,134,690,588.2 | 21,008,000,532.03 | 15,089,979,241.8 | 9,756,000,390.11 |
| 营业成本 | 1,068,662,516.36 | 3,848,177,391.88 | 2,833,182,677.7 | 1,873,303,655.38 |
| 税金及附加 | 60,059,261.23 | 257,883,958.62 | 172,414,995.14 | 114,951,556.98 |
| 销售费用 | 1,967,222,708.33 | 8,336,069,025.76 | 6,109,287,761.42 | 3,938,214,500.02 |
| 管理费用 | 586,082,025.59 | 2,555,686,849.29 | 1,874,111,722.11 | 1,173,998,524.87 |
| 研发费用 | 1,533,207,293.28 | 6,582,915,544.87 | 4,548,870,345.14 | 3,037,753,778.66 |
| 财务费用 | -80,543,216.59 | -572,732,238.39 | -447,888,259.71 | -382,221,625.8 |
| 其中:利息费用 | 10,924,238.97 | 5,558,751.08 | 3,313,597.64 | 3,314,241.63 |
| 其中:利息收入 | 77,065,178.29 | 603,277,309.6 | 490,918,277.37 | 370,788,078.84 |
| 加:公允价值变动收益 | -13,112,706.36 | 108,630,771.57 | 9,529,744.94 | 7,542,196.34 |
| 加:投资收益 | -6,818,455.69 | 4,279,363.56 | -31,420,370.48 | -16,140,088.65 |
| 资产处置收益 | 1,038,858.19 | 5,397,912.01 | 2,149,624.8 | 2,015,408.01 |
| 资产减值损失(新) | -1,395,839.13 | -32,538,341.38 | 9,250,184.59 | 15,816,450.54 |
| 信用减值损失(新) | 7,544,663.8 | 28,997,491.04 | -14,287,748.84 | -37,500,577.09 |
| 其他收益 | 27,803,856.33 | 399,259,997.05 | 270,744,490.42 | 168,309,001.73 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 2,085,980,911.66 | 7,490,632,003.88 | 5,345,290,528.73 | 3,984,776,115.54 |
| 加:营业外收入 | 623,478.59 | 10,446,041.92 | 5,790,924.24 | 3,132,564.37 |
| 减:营业外支出 | 11,000,678.42 | 331,388,050.05 | 264,341,297.74 | 236,308,575.04 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 2,075,603,711.83 | 7,169,689,995.75 | 5,086,740,155.23 | 3,751,600,104.87 |
| 减:所得税费用 | 199,161,750.51 | 832,695,348.22 | 470,409,977.77 | 323,467,746.83 |
| 六、净利润 | 1,876,441,961.32 | 6,336,994,647.53 | 4,616,330,177.46 | 3,428,132,358.04 |
| 持续经营净利润 | 1,876,441,961.32 | 6,336,994,647.53 | 4,616,330,177.46 | 3,428,132,358.04 |
| 归属于母公司股东的净利润 | 1,874,055,519.98 | 6,336,527,014.75 | 4,619,575,874.29 | 3,431,748,098.1 |
| 少数股东损益 | 2,386,441.34 | 467,632.78 | -3,245,696.83 | -3,615,740.06 |
| (一)基本每股收益 | 0.3 | 1 | 0.73 | 0.54 |
| (二)稀释每股收益 | 0.3 | 1 | 0.73 | 0.54 |
| 八、其他综合收益 | 2,346,805.44 | -624,026.11 | -12,630,993.15 | -17,226.74 |
| 归属于母公司股东的其他综合收益 | 2,446,707.84 | -2,352,161.55 | -11,499,309.03 | -772,837.34 |
| 九、综合收益总额 | 1,878,788,766.76 | 6,336,370,621.42 | 4,603,699,184.31 | 3,428,115,131.3 |
| 归属于母公司股东的综合收益总额 | 1,876,502,227.82 | 6,334,174,853.2 | 4,608,076,565.26 | 3,430,975,260.76 |
| 归属于少数股东的综合收益总额 | 2,286,538.94 | 2,195,768.22 | -4,377,380.95 | -2,860,129.46 |
| 公告日期 | 2025-04-25 | 2025-03-31 | 2024-10-25 | 2024-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |